Journal of Drug Vigilance and Alternative Therapies (JDVAT) is a peer-reviewed, open access journal. JDVAT publishes the original works like research article, review article, case study, short communication and letter to editor quarterly. The journal covers various subjects related to Natural Sciences, Pharmacovigilance, Herbalism, Traditional, Complementary and Combination therapies. The journal aims to identify the adverse drug reactions of new as well as existing drugs, to confirm their impacts and to develop different methods to reduce or prevent adverse drug effects we encourage papers referring to global medical studies of reducing adverse effects of existing and new drugs.
An original submitted manuscript will be reviewed for conceivable international publication with the perceptive that it is being exclusively submitted to Journal of Drug Vigilance and Alternative Therapies (JDVAT). The manuscript should not be published previously or submitted anywhere. All received original copies of manuscripts are duly acknowledged. At first after submission, journal editors will review the submitted manuscripts for appropriateness and preciseness. Manuscripts will be rejected if they are found to have inadequate and deficient originality, serious scientific or technical errors, and lack of a significant message before proceeding for formal peer-review. Manuscripts that are dubious for readers of Journal of Drug Vigilance and Alternative Therapies are also liable to be rejected at this stage itself. Please note that JDVAT does not retain copies of rejected articles.
Every manuscript is assigned to a member of the editorial team for a final decision on the manuscript based on the comments from the reviewers. The comments and suggestions acceptance/rejection/amendments received from reviewers are conveyed to the corresponding author. Manuscripts accepted for publication are copy edited for grammar, punctuation, print style, and format. Page proofs are sent to the corresponding author. The corresponding author is expected to return the corrected proofs after corrections.
Clinical Trial Registry
The Journal of Drug Vigilance and Alternative Therapies encourage clinical trial registration and is a signatory to the Statement on clinical trial publication in Indian biomedical journals. Clinical trials that have been licensed with a clinical trial registry that provides free digital access to the public will be published in the Journal of Drug Vigilance and Alternative Therapies.
Only broad contributions and involvement can get the authorship recognition. Authorship credit is earned by contributing to the study's concept and execution, as well as securing records, investigating, and interpreting data. Participation primarily in the procurement of funds or the compilation of data does not justify authorship. Authorship would not provide general oversight of the research group. Each contributor should have contributed enough to the project to accept public responsibility for acceptable portions of the manuscript's material. Based on the type of manuscript, its length, and the number of entities concerned, the journal specifies a maximum number of authors.
Conflicts of Interest/Competing Interests
All authors shall report any and all potential conflicts of interest they may have with the manuscript's publication, or with an organization or commodity listed in the manuscript and/or relevant to the study's outcome. Conflicts of interest with goods that compete with those listed in the manuscript should also be disclosed.
Submission of Manuscripts
Articles can be uploaded in ‘.doc’ format through Online Submission System or can be mailed to email@example.com. After receiving the article, an article number will be generated and mailed to the person submitting document.
Please feel free to contact the managing editor office via e-mail at firstname.lastname@example.org if you have any issues during submission process.
All articles should be accompanied by a cover letter that includes the author's full address as well as a phone number and fax number. Manuscripts that do not follow the "Instructions to Authors" will be reverted to the authors for technical correction before moving into the editorial/peer review process.
The manuscript should be submitted in three different files:
1. Title Page File and Covering letter to Editor:
On title page, the authors must have a short title, author name(s), desired degree (one only), affiliation(s), and full address (es). The accompanying author's name and address, as well as email and phone numbers, should be mentioned separately and explicitly. This file should provide the covering letter followed by mentioning type of manuscript (original article, case report, review article, Letter to editor, Images, etc.) and title of the manuscript. One or more statements should specify acknowledgments of technical help; and acknowledgments of financial and material support, which should specify the nature of the support. Write the registration number in case of a clinical trial and where it is registered (name of the registry and its URL) and conflicts of Interest of each author/ contributor. The name, address, e-mail, and telephone number of the corresponding author, who is responsible for communicating with the other authors about revisions and final approval of the proofs is to be included.
2. The Declaration/Authorization/Copyright Transfer Form (template provided)
Copyright form has to be submitted in original with the signatures of all the contributors after the acceptance of submission via courier, fax or email as a scanned image. Download the copyright transfer form from website and submitted online to email@example.com.
3. Article Files:
The main text of the article, beginning from Abstract till References (including figures & tables) should be in this file. The file must not mention the authors' names or initials or the institution at which the study was done or acknowledgements. Title/running title can include but not the authors names. The pages should be numbered consecutively, beginning with the first page of the article file.
PREPARATION OF MANUSCRIPT
Manuscripts must be prepared in accordance with "Uniform requirements for Manuscripts submitted to Biomedical Journals" developed by the International Committee of Medical Journal Editors. The Journal of Drug Vigilance and Alternative Therapies request the contributors to kindly adhere to the following requirements:
Articles should be in A4 Size Page with 1" margin from all four sides and line spacing of 1.5. American English should be used with size 12 pt and font: Cambria. Headings should be in capitals followed by sub-headings in both Upper and Lower Case letter and numbered such as 1, 1.1, 1.1.1 etc. till conclusion. Write the full term for each abbreviation at its first use. Check the manuscript for spelling, grammar and punctuation errors. If a brand name is cited, supply the manufacturer's name and address (city and state/country). Species names should be in italics. Tables should be numbered as Table 1: (Title), Table 2: (Title) etc. and figures should be numbered as Fig. 1: (Title), Fig. 2: (Title) etc. The non-standard abbreviations used in each table should be explained in footnotes. For all entirely borrowed, adapted, and updated tables, obtain permission and include a credit line in the footnote. Labels, numbers, and symbols should all be large and legible in the figures and graphs. The legends for illustrations should include titles and extensive descriptions. If a figure has been published somewhere, credit the original source and obtain written permission to replicate the content from the copyright holder.
Copies of Any Permission(s)
It is the duty of authors/contributors to acquire permissions for reproducing any copyrighted material. Copies of any and all published articles or other manuscripts in preparation or submitted elsewhere that are related to the manuscript must accompany the manuscript.
1. Original Articles
These include studies of screening and diagnostic test, randomized controlled trials, intervention studies, outcome studies, cost effectiveness analyses, case-control series, and surveys with high response rate. The text of original articles should be divided into sections with the headings, Abstract, Keywords, Introduction, Materials and Methods, Results, Discussion, Conclusion, Acknowledgements and References.
Abstract: A structured abstract is required which provide the context or background of the study and should state the study's purpose, basic procedures (selection of study participants, settings, measurements, analytical methods), main findings (giving specific effect sizes and their statistical and clinical significance, if possible), and principal conclusions. Standard nomenclature should be used and abbreviations and references should be avoided. It should be not more than 250 words.
Keywords: Provide three to six appropriate keywords after the abstract.
Introduction: Declare the study's or observation's intent and outline the reason for it.. Give description of what is relied upon to be discovered.
Materials and Methods: It should incorporate and depict the following aspects:
Ethics: Indicate if the protocols used were in compliance with the ethical principles of the competent committee on human experiments (institutional or regional) and the Helsinki Declaration of 1975, as amended in 2008 (available at https://www.wma.net/what-we-do/medical-ethics/declaration-of-helsinki/doh-oct2008/) when disclosing human studies. The approval of (regional/ national/ institutional or independent Ethics Committee or Review Board, obtaining informed consent from adult study subjects, and obtaining assent for children aged over 7 years involved in the trial are all required to be mentioned in prospective trials involving human participants. Indicate if the institutions or a national research council's guide for, or other national legislation on the treatment and use of laboratory animals, was observed when reporting animal studies.
Under the ‘Materials and Methods' clause, all research publications must contain a report on ethics committee permission and ethical practices. The authors must have evidence of acceptance by a local Ethics Committee (for both human and animal studies) on request. The usage of anesthetics and analgesics in animal experiments should be as ethical as practicable, and the information of the anesthetics and analgesics used should be mentioned explicitly. Experiments to follow the rules set out by the animals ethics committe and World Medical Association Declaration of Helsinki on Ethical Principles for Medical Research Involving Humans, respectively, for studies involving laboratory animals and human beings. Any article that is unethically objectionable would be rejected by the journal.
Study Design: Clearly describe that how observational or experimental subjects (patients or research animals) were selected, including their eligibility and how they were acquired.
Provide enough information about the processes, tools (including the company's names and addresses). Provide references to techniques and methods, particularly statistical methods, as well as short descriptions of new or significantly modified methods and the rationale for their use. Identify the medications and chemicals that were used, including their brand names, doses, and administration routes. Present quantitative results with sufficient measuring error or uncertainty measures. Describe the computer program that was used. P values should be written in upper italics (P < 0.000).
Results: This section should concentrate on achieving the goals set out in the introduction. It should include tables, graphs, and images to illustrate the results. Limit tables and figures to those that are needed to illustrate the paper's statement and determine its support. Use graphs instead of tables with a lot of entries; avoid duplicating data in graphs and tables.
Discussion: This section should be rational and follow the findings. It should also deal with the analysis of the results and how they help improve existing understanding of the problem. Assumptions that aren't backed by evidence should be discouraged. The discussion section should state the possibilities that need to be investigated further. Don't include the results and the discussion under one heading.
Conclusion: A brief conclusion must be included in the article, explicitly specifying the result and significance of the empirical study discussed. It can also describe the improvement in methods, if any in comparison to some older methods.
2. Review Articles
These articles should be published by people who have done a lot of research on the topic or are experts in the area. All of the formatting criteria are the same as for research papers. Provides a critical analysis of the literature that is definitive, reliable, detailed, and thoroughly referenced.
3. Benefit-Risk Assessment of Existing and New Drug
The benefit-risk 'equation' arises after an in-depth analysis of the adverse effect information and the clinical benefits of the drug. It should include a summary of patient groups vulnerable to adverse effects and comparative tolerability evidence where appropriate, as well as a consideration of the pharmacodynamic or pharmacokinetic basis of potential adverse reactions/interactions. It should balance the advantages and consequences of the drug agent in concern to provide the clinical and formulary decision-makers with the data they need to understand the benefit-risk relationship and safety of the drug agent.
4. Case Reports
Case reports simulates step-by-step emergence of information/developments of adverse drug reactions in clinical practice or during post market surveillance. It should describe the methods such as complementary and combination treatments to the clinicians or healthcare professionals through which the safety of patients can be achieved. Case reports are highly encouraged.
This chapter offers a forum for expert commentary on current public health topics that is well-referenced. Initiatives for reform, good practice policy, critique of current practice or regulation, and reactions to published comments are also examples of suitable submissions. The length should be limited to 1000 words with a detailed presentation of evidence and 10-15 references.
Perspectives address one or a group of newly scientific publications or a fiercely disputed research subject in which an author's point of view throws new light on key research findings. The aim of these papers is to keep our interdisciplinary readership up to date on exciting research discoveries in the author's field of expertise. Discussions of approaches, texts, or conference details are often relevant subjects. The approximate length of a perspective is between 2000 and 4000 words, including abstract, main text, references, figure and table legends. They should include a concise title, no more than 35 references, and one or two figures (with legends) or tables.
7. Letter to the Editor
Letters to the Editor are accepted for publication, subject to revision and abrogation, as long as they do not include content that has already been published or written.
References should strictly adhere to NLM style of citing references. They should be numbered consecutively in the order in which they are first mentioned in the text (not in alphabetic order). Identify references in text, tables and legends by Arabic numerals in superscript after the punctuations. References cited only in tables or figure legends should be numbered in accordance with the sequence established by the first identification in the text of the particular table or figure.
For Standard Journal Article
1. Remesh A. Toxicities of anticancer drugs and its management. Int J Basic Clin Pharmacol Medip Academy. 2012;1(1):2.
2. Matalka II, Mhaidat NM, Fatlawi LA. Antioxidant activity of simvastatin prevents L-arginine-induced acute toxicity of pancreas. Int J Physiol Pathophysiol Pharmacol. 2013 May 27;5(2):102-8.
For more than six authors, list the first six contributors followed by et al.
1. Diallo A, Gbeassor M, Vovor A, Eklu-Gadegbeku K, Aklikokou K, Agbonon A, et al. Effect of Tectona grandis on phenylhydrazine-induced anaemia in rats. Fitoterapia. 2008;79(5):332–336.
For Author of Textbook
Cheers B, Darracott R, Lonne B. Social care practice in rural communities. Sydney: The Federation Press; 2007;68-75.
For Reference of Website
Diabetes Australia. Gestational diabetes [Internet]. Canberra (ACT): Diabetes Australia; 2015 [updated 2015; cited 2020 Nov 23]. Available from: https://www.diabetesaustralia.com.au/gestational-diabetes
There is no article submission charges. Publication of articles in JDVAT requires Article Processing Charges of INR 2250/- for processing and publication of the accepted manuscripts from India and $54/- outside India. International articles should be charged based on their country's financial status in World Bank classification list. The journal maintains a "quarterly publishing" schedule and posts articles on its website on 30th of each quarterly month.
We waive Article Processing Charges for authors based on the World Bank's classification of Author's country. The author(s) requesting a waiver must make a compelling argument for why their requests should be granted. We reserve the right to grant or deny a waiver request. Within one week after receiving the application, the waiver decision will be informed to the associated author.